KR940021064A - 프레그네인 유도체의 사용 방법 - Google Patents

프레그네인 유도체의 사용 방법 Download PDF

Info

Publication number
KR940021064A
KR940021064A KR1019940004180A KR19940004180A KR940021064A KR 940021064 A KR940021064 A KR 940021064A KR 1019940004180 A KR1019940004180 A KR 1019940004180A KR 19940004180 A KR19940004180 A KR 19940004180A KR 940021064 A KR940021064 A KR 940021064A
Authority
KR
South Korea
Prior art keywords
methyl
hydroxy
compound
derivative
treating
Prior art date
Application number
KR1019940004180A
Other languages
English (en)
Other versions
KR100312061B1 (ko
Inventor
헤르마누스 조한나 덱커스 고데프리두스
잔 클로오스터보어 헬레니우스
Original Assignee
에프.쥐.엠.헤르만스 · 에이.쥐.제이.베르미어렌
악조 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프.쥐.엠.헤르만스 · 에이.쥐.제이.베르미어렌, 악조 엔.브이. filed Critical 에프.쥐.엠.헤르만스 · 에이.쥐.제이.베르미어렌
Publication of KR940021064A publication Critical patent/KR940021064A/ko
Application granted granted Critical
Publication of KR100312061B1 publication Critical patent/KR100312061B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Fats And Perfumes (AREA)

Abstract

본 발명은 종양을 예방하거나 치료하기 위한 약제의 제조에 있어서, 하기 일반식을 갖는 프레그네인 유도체 및 특히 프레그네인 유도체 (7α,17α)-17-히드록시-7-메틸-19-노르-17-프레근-5(10)-엔-20-인-3-온(화합물 I)의 사용방법에 관한 것이다.
상기식중에서, R은 H2, (H,OH), (H,O아실), 또는 O이다.

Description

프레그네인 유도체의 사용방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 종양을 예방하거나 치료하기 위한 약제의 제조에 있어서, 하기 일반식을 갖는 프레그네인 유도체의 사용 방법;
    상기식중에서, R은 H2, (H,OH), (H,O아실), 또는 O이다.
  2. 제1항에 있어서, 상기 약제가 유방 종양을 예방하거나 치료하는데 사용됨을 특징으로 하는 사용방법.
  3. 제1항 또는 제2항에 있어서, 상기 유도체가 R이 (H,OH)인 [(7α,17α)-3,17-디히드록시-7-메틸-19-노르-17-프레근-5(10)-엔-20-인]임을 특징으로 하는 사용방법.
  4. 제1항 또는 제2항에 있어서, 상기 유도체가 R이 0인 [(7α,17α)-17-히드록시-7-메틸-19-노르-17-프레근-5(10)-엔-20-인-3-온(화합물 I)]임을 특징으로 하는 사용방법.
  5. 제4항에 있어서, 상기 프레그네인 유도체가 (7α,17α)-17-히드록시-7-메틸-19-노르-17-프레근-5(10)-엔-20-인-3-온 은 단사정 P21형태(화합물 II)를 갖고 있음을 특징으로 하는 사용방법.
  6. (7α,17α)-17-히드록시-7-메틸-19-노르-17-프레근-5(10)-엔-20-인-3-온의 유효량의 투여하는 것을 포함하는 종양의 치료방법.
  7. 단사정 P21형태를 갖는 (7α,17α)-17-히드록시-7-메틸-19-노르-17-프레근-5(10)-엔-20-인-3-온 의 유효량을 투여하는 것을 포함하는 종양의 치료방법.
  8. (7α,17α)-17-디히드록시-7-메틸-19-노르-17-프레근-5(10)-엔-20-인의 유효량을 투여하는 것을 포함하는 종양의 치료방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940004180A 1993-03-05 1994-03-04 프레그네인유도체의사용방법 KR100312061B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP93200631 1993-03-05
NL93200631.5 1993-03-05
EP93200631.5 1993-03-05

Publications (2)

Publication Number Publication Date
KR940021064A true KR940021064A (ko) 1994-10-17
KR100312061B1 KR100312061B1 (ko) 2001-12-28

Family

ID=8213673

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940004180A KR100312061B1 (ko) 1993-03-05 1994-03-04 프레그네인유도체의사용방법

Country Status (14)

Country Link
US (1) US5512556A (ko)
EP (1) EP0613687B1 (ko)
JP (1) JP3391539B2 (ko)
KR (1) KR100312061B1 (ko)
AT (1) ATE180669T1 (ko)
AU (1) AU671706B2 (ko)
CA (1) CA2116829C (ko)
DE (1) DE69418744T2 (ko)
DK (1) DK0613687T3 (ko)
ES (1) ES2134313T3 (ko)
GR (1) GR3031114T3 (ko)
NO (1) NO307447B1 (ko)
NZ (1) NZ260017A (ko)
ZA (1) ZA941464B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009056A1 (en) * 1994-09-22 1996-03-28 Akzo Nobel N.V. Process of making dosage units by wet granulation
IL123984A (en) * 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable
ES2197677T3 (es) * 1998-10-16 2004-01-01 Akzo Nobel N.V. Composiciones de alta pureza que comprenden (7alfa-17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5(10)-en-20-in-3-ona.
ATE246703T1 (de) * 1999-04-06 2003-08-15 Akzo Nobel Nv Oral wirksame 7-alpha-alkyl androgene
ATE295851T1 (de) 1999-09-06 2005-06-15 Akzo Nobel Nv Nicht-aromatische estrogenische steroide mit einem 11-hydrocarbyl substituent
ATE294812T1 (de) 2000-07-28 2005-05-15 Akzo Nobel Nv 16alpha-methyl oder ethyl substituierte oestrogene
MXPA04003588A (es) * 2001-10-18 2005-04-11 Norton Healthcare Ltd Nuevas formulaciones de tibolona.
GB0125061D0 (en) * 2001-10-18 2001-12-12 Norton Healthcare Ltd Pharmaceutical composition
RU2004125594A (ru) * 2002-01-22 2005-03-10 Акцо Нобель Н.В. (NL) Применение тиболона при лечение симптомов, связанных с введением лекарств, препятствующих синтезу эндогенного эстрогена
US20060051420A1 (en) * 2002-11-20 2006-03-09 Pieter De Haan Pharmaceutical tablets containing tibolone and a coating
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
US20060211667A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of pregnane steroid derivatives for enhancing physical performance
CN116987680A (zh) * 2022-04-25 2023-11-03 复旦大学 支链氨基酸转氨酶1的功能获得性突变体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
IE63051B1 (en) * 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
FR2706454B1 (fr) * 1993-06-17 1995-09-15 Roussel Uclaf Nouveaux 19-Nor stéroïdes, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
AU5754294A (en) 1994-09-08
DK0613687T3 (da) 1999-12-06
EP0613687A1 (en) 1994-09-07
CA2116829C (en) 2004-09-14
NO307447B1 (no) 2000-04-10
ES2134313T3 (es) 1999-10-01
NZ260017A (en) 1997-06-24
CA2116829A1 (en) 1994-09-06
NO940777L (no) 1994-09-06
US5512556A (en) 1996-04-30
ATE180669T1 (de) 1999-06-15
NO940777D0 (no) 1994-03-04
EP0613687B1 (en) 1999-06-02
GR3031114T3 (en) 1999-12-31
JPH072673A (ja) 1995-01-06
JP3391539B2 (ja) 2003-03-31
AU671706B2 (en) 1996-09-05
DE69418744D1 (de) 1999-07-08
KR100312061B1 (ko) 2001-12-28
DE69418744T2 (de) 1999-11-11
ZA941464B (en) 1994-09-27

Similar Documents

Publication Publication Date Title
KR940021064A (ko) 프레그네인 유도체의 사용 방법
KR910004651A (ko) 5α-환원효소 억제제로서의 17β-아실-4-아자-5α-안드로스트-1-엔-3-온
KR950031068A (ko) 골다공증의 복합 치료
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
DE69433889D1 (de) Anwendung von 1,2,4-benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
TR199801244T2 (xx) Herpese kar�� �zellikler ta��yan fenil tiyazol t�revleri.
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
DE69320646D1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
KR970074765A (ko) 비타민 d₃ 동족체
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
KR950010891A (ko) 내성 종양을 치료하는 방법
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
KR910004191A (ko) 신질환치료제
KR960030947A (ko) src SH2 특이성 화합물의 골흡수 질환 치료 용도
KR930700163A (ko) 연조직 종양의 치료 및/또는 진단 방법
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
KR890017363A (ko) 스트로빌루린 유도체, 이들의 제법 및 용도
KR910011820A (ko) Ltb4 합성 저해제
KR900701273A (ko) 진토성 에르골린 유도체
KR900017599A (ko) 종양 치료용 약학 조성물
KR960703010A (ko) 고사 유도제(apoptosis inducer)
KR940005541A (ko) 치환된 벤조에이트 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060928

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee